GlassScriptPhysician profile
Kiyon Chung
NPI 1972517910
$7,237.96
in general payments reported to CMS, 2019-2025
25 companies · $769 in 2025
The $769 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $328 · 2020: $565 · 2021: $711 · 2022: $698 · 2023: $779 · 2024: $3,387 · 2025: $769.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,820 · Food and Beverage: $2,116.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,820.00 |
| Food and Beverage | $2,115.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $2,959.63 | 2022-2025 | (2858) General Consulting, (5044) Mcot, Mcot |
| Novartis Pharmaceuticals Corporation | $1,090.36 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $622.45 | 2021-2025 | Verquvo |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $495.82 | 2019-2023 | Lifevest |
| Pfizer INC. | $267.45 | 2019-2025 | |
| Actelion Pharmaceuticals US, INC. | $236.48 | 2019-2025 | Uptravi, Opsumit, Opsynvi |
| Aop Health US, LLC | $223.35 | 2025 | Rapiblyk |
| E.R. Squibb & Sons, L.L.C. | $211.15 | 2020-2025 | Camzyos, Eliquis |
| Abbott Laboratories | $176.15 | 2021-2025 | Aveir, Gallant, Mitraclip |
| Astrazeneca Pharmaceuticals LP | $172.20 | 2019-2025 | Farxiga, Andexxa |
| Biotronik Nro, INC. | $129.04 | 2025 | Prospera |
| Boehringer Ingelheim Pharmaceuticals, INC. | $117.16 | 2020-2023 | Jardiance |
| Janssen Pharmaceuticals, INC | $78.52 | 2019-2022 | |
| Cvrx, INC. | $62.92 | 2022-2025 | Barostim Neo System |
| Baxter Healthcare | $62.11 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals, LTD. | $50.72 | 2021-2022 | |
| Alnylam Pharmaceuticals INC. | $50.07 | 2022 | |
| Kestra Medical Technology Services, INC. | $43.36 | 2024 | Assure Wcd |
| Irhythm Technologies, INC. | $41.71 | 2022-2024 | Zio Monitor, Zio Xt Patch |
| Amgen INC. | $33.32 | 2024-2025 | Repatha |
| Medtronic, INC. | $31.91 | 2023 | Micra |
| Lilly USA, LLC | $25.54 | 2025 | Mounjaro |
| Coala Life INC | $22.70 | 2022 | |
| Getinge USA Sales, LLC | $18.44 | 2025 | Cardiosave Rescue |
| W. L. Gore & Associates, INC. | $15.40 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kiyon Chung listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.